ATE513042T1 - Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung - Google Patents

Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung

Info

Publication number
ATE513042T1
ATE513042T1 AT06075363T AT06075363T ATE513042T1 AT E513042 T1 ATE513042 T1 AT E513042T1 AT 06075363 T AT06075363 T AT 06075363T AT 06075363 T AT06075363 T AT 06075363T AT E513042 T1 ATE513042 T1 AT E513042T1
Authority
AT
Austria
Prior art keywords
tumor
acid sequences
fusion proteins
sequences encoding
associated antigen
Prior art date
Application number
AT06075363T
Other languages
English (en)
Inventor
Silva Teresa Cabezon
Joseph Cohen
Moncef Mohamed Slaoui
Bassols Carlota Vinals
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802543.0A external-priority patent/GB9802543D0/en
Priority claimed from GBGB9802650.3A external-priority patent/GB9802650D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE513042T1 publication Critical patent/ATE513042T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
AT06075363T 1998-02-05 1999-02-02 Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung ATE513042T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9802543.0A GB9802543D0 (en) 1998-02-05 1998-02-05 Vaccine
GBGB9802650.3A GB9802650D0 (en) 1998-02-06 1998-02-06 Vaccine

Publications (1)

Publication Number Publication Date
ATE513042T1 true ATE513042T1 (de) 2011-07-15

Family

ID=26313069

Family Applications (4)

Application Number Title Priority Date Filing Date
AT05076599T ATE505542T1 (de) 1998-02-05 1999-02-02 Tumorassoziierte antigenderivate der mage-familie,zur herstellung von fusionsproteinen mit t-helper epitope und zusammensetzungen zur impfung
AT99907476T ATE315088T1 (de) 1998-02-05 1999-02-02 Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
AT06075362T ATE462788T1 (de) 1998-02-05 1999-02-02 Verfahren zur reinigung oder herstellung der mage protein
AT06075363T ATE513042T1 (de) 1998-02-05 1999-02-02 Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung

Family Applications Before (3)

Application Number Title Priority Date Filing Date
AT05076599T ATE505542T1 (de) 1998-02-05 1999-02-02 Tumorassoziierte antigenderivate der mage-familie,zur herstellung von fusionsproteinen mit t-helper epitope und zusammensetzungen zur impfung
AT99907476T ATE315088T1 (de) 1998-02-05 1999-02-02 Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
AT06075362T ATE462788T1 (de) 1998-02-05 1999-02-02 Verfahren zur reinigung oder herstellung der mage protein

Country Status (26)

Country Link
US (3) US8097257B2 (de)
EP (4) EP1659179B1 (de)
JP (2) JP4768121B2 (de)
KR (2) KR100824105B1 (de)
CN (1) CN1227360C (de)
AR (1) AR018064A1 (de)
AT (4) ATE505542T1 (de)
AU (1) AU737337B2 (de)
BR (1) BR9907691B1 (de)
CA (2) CA2584482C (de)
CY (4) CY1105685T1 (de)
CZ (2) CZ298347B6 (de)
DE (3) DE69929310T2 (de)
DK (4) DK1659179T3 (de)
ES (2) ES2255248T3 (de)
HK (4) HK1033838A1 (de)
HU (1) HU228467B1 (de)
IL (4) IL137442A0 (de)
NO (2) NO328507B1 (de)
NZ (1) NZ506086A (de)
PT (4) PT1584685E (de)
SA (1) SA99200126B1 (de)
SI (4) SI1659179T1 (de)
TR (1) TR200002284T2 (de)
TW (1) TWI238853B (de)
WO (1) WO1999040188A2 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1659179B1 (de) 1998-02-05 2011-06-15 GlaxoSmithKline Biologicals s.a. Tumorassoziierte Antigenderivate der Mage-Familie, Nukleinsäuresequenzen, die dafür kodieren, zur Herstellung von Fusionsproteinen und Zusammensetzungen zur Impfung
DE69918146T2 (de) 1998-10-05 2005-07-07 Pharmexa A/S Verfahren zur therapeutischen impfung
EP1502602A3 (de) * 1998-10-05 2006-05-17 Pharmexa A/S Verfahren zur therapeutischen Impfung
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
KR20090085697A (ko) * 2000-02-23 2009-08-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 종양 특이적 동물 단백질
EP1385541B1 (de) * 2000-04-13 2008-06-18 Corixa Corporation Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
AU2001258102B2 (en) * 2000-05-10 2007-03-01 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
AUPQ761200A0 (en) 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
DE60140868D1 (de) * 2000-06-05 2010-02-04 Brigham & Womens Hospital Für ein homologes des humanen, für mehrfachresistenz verantwortlichen, p-glykoproteins auf chromosom 7p15-21 kodierendes gen sowie verwendungen dafür
CA2413959C (en) 2000-06-20 2015-07-07 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
CA2425358C (en) * 2000-10-18 2012-08-21 Glaxosmithkline Biologicals S.A. A vaccine composition comprising qs21, mpl, a cpg oligonucleotide and a cancer antigen
ES2392943T3 (es) 2000-10-18 2012-12-17 Glaxosmithkline Biologicals S.A. Vacunas antitumorales
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US8921534B2 (en) 2001-12-12 2014-12-30 Sanofi Pasteur Limited Enhancement of the immune response using CD36-binding domain
EP1925626A1 (de) 2003-07-21 2008-05-28 Transgene S.A. Neue multifunktionelle Cytokine
WO2005021588A1 (en) * 2003-08-29 2005-03-10 The Nottingham Trent University Gastric and prostate cancer associated antigens
AU2004281634B2 (en) * 2003-09-03 2011-01-27 Dendritherapeutics, Inc. Multiplex vaccines
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
EP2386314A1 (de) 2005-03-31 2011-11-16 GlaxoSmithKline Biologicals SA Impfstoff gegen Chlamydieninfektion
EP2426141B1 (de) 2005-04-29 2014-10-01 GlaxoSmithKline Biologicals S.A. Verfahren zur Vorbeugung oder Behandlung einer M-tuberculosis-Infektion
WO2006125821A2 (en) * 2005-05-26 2006-11-30 Cytos Biotechnology Ag Scalable fermentation process
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007053956A1 (en) * 2005-11-14 2007-05-18 Universite Laval Cancer antigen mage-a9 and uses thereof
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP5170976B2 (ja) 2006-04-11 2013-03-27 株式会社イミュノフロンティア タンパク質複合体およびその製造方法
EP2390364A1 (de) 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals S.A. Verfahren zur Indentifizierung des Ansprechens bzw. Nichtansprechens eines Patienten auf eine Immuntherapie basierend auf die Differentielle Expression vom Gen PRKCQ
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
SI2484375T1 (en) 2006-09-26 2018-08-31 Infectious Disease Research Institute A vaccine composition comprising a synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy
NZ578285A (en) * 2007-01-15 2011-12-22 Glaxosmithkline Biolog Sa Fusion protein comprising a prame linked to a immunological fusion partner protein and additional amino acids at the n terminal end of the fusion partner sequence
JP2010539027A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのペプチドの使用
WO2009039986A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-αrg as a therapeutic agent
MX2010002965A (es) 2007-09-17 2010-09-14 Oncomethylome Sciences Sa Deteccion mejorada de la expresion de mage-a.
EP2200642B1 (de) * 2007-10-19 2012-04-18 Novartis AG Meningokokkenimpfstoffformulierungen
BRPI1009873A2 (pt) 2009-03-17 2016-03-08 Glaxosmithkline Biolog Sa detecção aperfeiçoada de expressão gênica
MA33409B1 (fr) 2009-05-27 2012-07-03 Glaxosmithkline Biolog Sa Produits de recombinaisoon de casb7439
SI2437753T1 (sl) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
MY156697A (en) 2010-01-27 2016-03-15 Glaxosmithkline Biolog Sa Modified tuberculosis antigens
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
CA2826920A1 (en) 2011-02-15 2012-08-23 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
EP3632463A1 (de) 2011-04-08 2020-04-08 Immune Design Corp. Immunogene zusammensetzungen und verfahren zur verwendung der zusammensetzungen zur induzierung humoraler und zellulärer immunreaktionen
CN102251034B (zh) * 2011-07-05 2012-11-21 北京大学人民医院 基于mage-c2/ct10基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
UA116528C2 (uk) 2011-08-30 2018-04-10 Астекс Фармасьютікалз, Інк. Склад, набір, фармацевтична композиція, що містять похідні децитабіну, їх отримання і застосування
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
KR20140107576A (ko) * 2011-12-22 2014-09-04 글락소스미스클라인 엘엘씨 Braf 저해제 및/또는 mek 저해제와 magea3 면역치료제를 이용한 암 치료 방법
TR201908003T4 (tr) 2012-02-07 2019-06-21 Infectious Disease Res Inst TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
KR102136433B1 (ko) 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
EP2961388B1 (de) 2013-03-01 2019-04-24 Astex Pharmaceuticals, Inc. Arzneimittelkombinationen
US8957047B2 (en) 2013-04-18 2015-02-17 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
IL246456B1 (en) 2013-12-31 2024-02-01 Access To Advanced Health Inst Formulations will be assembled into a single vial
EA035259B1 (ru) 2014-02-14 2020-05-21 Иммьюн Дизайн Корп. Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
JP2017522312A (ja) 2014-07-15 2017-08-10 イミューン デザイン コーポレイション Ｔｌｒ４アゴニストアジュバント及びレンチウイルスベクターを用いたプライム・ブーストレジメン
WO2017004538A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
CN105181966B (zh) * 2015-09-02 2017-08-11 南通大学附属医院 一种mage‑a9的用途
KR102566134B1 (ko) 2015-12-07 2023-08-10 삼성전자주식회사 반도체 소자의 3d 프로파일링 시스템 및 이의 동작 방법
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
CA3020542A1 (en) 2016-04-11 2017-10-19 Board Of Regents, The University Of Texas System Methods and compositions for detecting single t cell receptor affinity and sequence
US11266602B2 (en) 2016-05-16 2022-03-08 Infectious Disease Research Institute PEGylated liposomes and methods of use
JP7195148B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｔｌｒアゴニストを含有する製剤及び使用方法
RU2753874C2 (ru) 2016-06-01 2021-08-24 Инфекшес Дизис Рисёрч Инститьют Наноалюмочастицы, содержащие агент, регулирующий размер
BR112019026615B1 (pt) 2017-06-15 2022-08-02 Infectious Disease Research Institute Carreadores lipídicos nanoestruturados e emulsões estáveis e usos dos mesmos
WO2019025863A2 (en) 2017-08-03 2019-02-07 Otsuka Pharmaceutical Co., Ltd. MEDICAMENT COMPOUND AND METHODS OF PURIFICATION
CA3078223A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
WO2020106621A1 (en) 2018-11-19 2020-05-28 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
EP3887518A2 (de) 2018-11-28 2021-10-06 Board of Regents, The University of Texas System Multiplexe genomeditierung von immunzellen zur erhöhung der funktionalität und resistenz gegenüber einer suppressiven umgebung
EP3886874A1 (de) 2018-11-29 2021-10-06 Board of Regents, The University of Texas System Verfahren zur ex-vivo-expansion von natürlichen killerzellen und verwendung davon
US20220249646A1 (en) 2019-05-25 2022-08-11 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
CA3168337A1 (en) 2020-02-17 2021-08-26 Marie-Andree Forget Methods for expansion of tumor infiltrating lymphocytes and use thereof
WO2022051024A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Genetically-adjuvanted rna vaccines
WO2022051022A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Co-lyophilized rna and nanostructured lipid carrier
WO2022104109A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
US20220162288A1 (en) 2020-11-25 2022-05-26 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
KR20230148148A (ko) 2020-12-23 2023-10-24 액세스 투 어드밴스드 헬스 인스티튜트 솔라네솔 백신 보조제 및 이의 제조 방법
EP4169513A1 (de) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Hilfsstoffzusammensetzung enthaltend sting agonisten
WO2023089556A1 (en) 2021-11-22 2023-05-25 Pfizer Inc. Reducing risk of antigen mimicry in immunogenic medicaments
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302386A (en) 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4384995A (en) 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US4526716A (en) 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
AR241713A1 (es) 1984-08-30 1992-11-30 Smithkline Beckman Corp Molecula de dna con una secuencia de bases que codifica la proteina c13 y preparacion de vacunas contra la gripe.
ZA896627B (en) * 1988-08-31 1991-03-27 Smithkline Beecham Corp Vaccinal polypeptides
GB8824496D0 (en) 1988-10-19 1988-11-23 Beecham Group Plc Process
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
CA2022752C (en) * 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2087969C (en) 1990-07-23 2001-10-16 Mark J. Murray Protease resistant pdgf and methods of use
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5925729A (en) 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
DE69231666T2 (de) * 1991-11-14 2001-05-10 Brigham & Womens Hospital Die nitrosylierung von enzym-sh gruppen als eine therapeutische massnahme
GB9213559D0 (en) 1992-06-25 1992-08-12 Smithkline Beecham Biolog Vaccines
ATE156710T1 (de) 1992-06-25 1997-08-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
ES2225824T3 (es) 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
CA2168582A1 (en) * 1993-08-06 1995-02-16 John D. Fikes Cloning and characterization of the complete mage-1 gene
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JPH09509832A (ja) 1994-03-01 1997-10-07 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ Ｍａｇｅ−３遺伝子発現による癌状態の判定
US5879687A (en) * 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
AU690371B2 (en) * 1994-09-30 1998-04-23 Ludwig Institute For Cancer Research Compositions containing tumor rejection antigen precursors or tumor rejection antigens, and an adjuvant and/or growth factor
US5612030A (en) * 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US6017705A (en) 1995-03-14 2000-01-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-B family and uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2224662A1 (en) 1995-06-29 1997-01-16 Ludwig Institute For Cancer Research Isolated nucleic acid molecule which encodes murine tumor rejection antigen precursor smage-3
WO1997013858A2 (en) 1995-10-12 1997-04-17 Chiron Corporation Baboon mage-3 homologs, dna encoding the homologs, and a process for their use
US6265215B1 (en) 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
US5908778A (en) 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
US6030780A (en) 1996-10-15 2000-02-29 The Rockefeller University Purified Stat proteins and methods of purifying thereof
EP0941366A2 (de) 1996-11-06 1999-09-15 Whitehead Institute For Biomedical Research Biallelische marker
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
WO1998026747A2 (en) 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
US6287569B1 (en) 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US20020176865A1 (en) 1997-04-25 2002-11-28 Sophie Lucas Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B families and uses thereof
US6027924A (en) 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US6043084A (en) 1997-10-10 2000-03-28 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
EP1659179B1 (de) 1998-02-05 2011-06-15 GlaxoSmithKline Biologicals s.a. Tumorassoziierte Antigenderivate der Mage-Familie, Nukleinsäuresequenzen, die dafür kodieren, zur Herstellung von Fusionsproteinen und Zusammensetzungen zur Impfung
AU3371199A (en) 1998-04-09 1999-11-01 Whitehead Institute For Biomedical Research Biallelic markers
US6686147B1 (en) 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor

Also Published As

Publication number Publication date
NZ506086A (en) 2003-01-31
CZ298364B6 (cs) 2007-09-05
EP1659179A3 (de) 2007-01-17
HK1093521A1 (en) 2007-03-02
JP2002502604A (ja) 2002-01-29
PT1659178E (pt) 2010-06-28
PL342852A1 (en) 2001-07-16
DE69929310D1 (de) 2006-03-30
ES2255248T3 (es) 2006-06-16
CZ298347B6 (cs) 2007-09-05
NO20091665L (no) 2000-10-04
ES2342416T3 (es) 2010-07-06
WO1999040188A2 (en) 1999-08-12
CN1295616A (zh) 2001-05-16
CZ20002869A3 (cs) 2001-01-17
BR9907691B1 (pt) 2011-05-31
EP1659178A2 (de) 2006-05-24
EP1053325A2 (de) 2000-11-22
TWI238853B (en) 2005-09-01
HK1033838A1 (en) 2001-09-28
JP2009201510A (ja) 2009-09-10
SA99200126B1 (ar) 2006-08-20
BR9907691A (pt) 2000-11-14
EP1053325B1 (de) 2006-01-04
CA2319309A1 (en) 1999-08-12
IL137442A (en) 2008-04-13
IL188875A (en) 2011-08-31
PT1053325E (pt) 2006-05-31
NO20003958D0 (no) 2000-08-04
AU737337B2 (en) 2001-08-16
IL137442A0 (en) 2001-07-24
US8097257B2 (en) 2012-01-17
US20100204458A1 (en) 2010-08-12
EP1659179A2 (de) 2006-05-24
PT1659179E (pt) 2011-09-16
DK1659179T3 (da) 2011-10-10
SI1584685T1 (sl) 2011-07-29
EP1584685A2 (de) 2005-10-12
HU228467B1 (en) 2013-03-28
AR018064A1 (es) 2001-10-31
IL188875A0 (en) 2009-02-11
EP1659178A3 (de) 2007-01-17
DK1584685T3 (da) 2011-07-11
IL179010A0 (en) 2007-03-08
CA2584482A1 (en) 1999-08-12
EP1659179B1 (de) 2011-06-15
US20100209444A1 (en) 2010-08-19
DE69929310T2 (de) 2006-08-03
SI1053325T1 (sl) 2006-06-30
ATE462788T1 (de) 2010-04-15
CY1110180T1 (el) 2015-01-14
US8044183B2 (en) 2011-10-25
EP1584685A3 (de) 2005-12-07
HUP0102639A1 (hu) 2001-11-28
SI1659179T1 (sl) 2011-10-28
CA2584482C (en) 2012-03-27
CY1111672T1 (el) 2015-10-07
NO331719B1 (no) 2012-03-05
EP1584685B1 (de) 2011-04-13
KR20060067977A (ko) 2006-06-20
DE69942214D1 (de) 2010-05-12
KR100633212B1 (ko) 2006-10-11
WO1999040188A3 (en) 1999-10-14
PT1584685E (pt) 2011-06-17
US8597656B2 (en) 2013-12-03
CY1111831T1 (el) 2015-10-07
EP1659178B1 (de) 2010-03-31
CY1105685T1 (el) 2010-12-22
KR100824105B1 (ko) 2008-04-21
KR20010040675A (ko) 2001-05-15
HK1083026A1 (en) 2006-06-23
HUP0102639A3 (en) 2004-04-28
ATE315088T1 (de) 2006-02-15
DK1659178T3 (da) 2010-07-12
JP4768121B2 (ja) 2011-09-07
HK1093522A1 (en) 2007-03-02
SI1659178T1 (sl) 2010-07-30
NO328507B1 (no) 2010-03-08
US20120269835A1 (en) 2012-10-25
NO20003958L (no) 2000-10-04
TR200002284T2 (tr) 2000-11-21
CN1227360C (zh) 2005-11-16
CA2319309C (en) 2010-08-10
DE69943359D1 (de) 2011-05-26
ATE505542T1 (de) 2011-04-15
AU2722099A (en) 1999-08-23
DK1053325T3 (da) 2006-05-22

Similar Documents

Publication Publication Date Title
ATE513042T1 (de) Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
DE50303749D1 (de) Verfahren zur herstellung von phthalocyaninpigmentzubereitungen
DE50201891D1 (de) Verfahren zur herstellung von 1-octen
DE60223070D1 (de) Verfahren zur herstellung von dihalogenadamantanen
DE60227718D1 (de) Verwendung von 2-Fuoro-3-Ketoestern zur Herstellung von 3-Fuoro-6,7,8,9-tetrahydro-4H-pyrimidoÄ1,2-aÜpyrimidin-4-onen
DE60223742D1 (de) Verfahren zur Herstellung von zusammengesetzten Farbstoff- Partikeln
DE60208738D1 (de) Verfahren zur Herstellung von Chlorfluorpolyoxyalkylenolen
DE60219193D1 (de) Verfahren zur herstellung von silylorganomercaptanen
DE60239842D1 (de) Verfahren zur Herstellung von 10,11-dihydro-10-oxo-5h-dibenzoÄb,fÜazepin-5-carboxamid
DE60200099D1 (de) Verfahren zur Herstellung von Isobutylenpolymeren
DE60233589D1 (de) Verfahren zur herstellung von echinocandinderivaten
DE50210487D1 (de) Verfahren zur Herstellung von 1-Amino-4-hydroxyanthrachinonen
DE60232433D1 (de) Verfahren zur herstellung von e-caprolactam
DE60209171D1 (de) Verfahren zur Herstellung von Bromfluorenen
DE60222806D1 (de) Verfahren zur herstellung von (1,4,5)-oxadiazepinderivaten
DE60108105D1 (de) Verfahren zur Herstellung von 5-substituierten Isobenzofuranen
DE50207073D1 (de) Verfahren zur Herstellung von Acyloxybenzolsulfonaten
DE60230097D1 (de) Verfahren zur herstellung von 1,5-diaminonaphthalinen
DE60026123D1 (de) Verfahren zur Herstellung von hitzevulkanisierbaren Silikonzusammensetzungen
WO2001092468A3 (en) Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof
DE69910155D1 (de) Verfahren zur Herstellung von Isobutylenglycol
DE60143350D1 (de) Verfahren zur herstellung von 1,3-dialkyl-2-imidazolidinon-derivaten
DE60234941D1 (de) Verfahren zur herstellung von cyclododecanon
DE60327567D1 (de) Verfahren zur herstellung von 3,3',4,4'-tetraaminobiphenyl
DE60108066D1 (de) Verfahren zur Herstellung von (-) 3,4 Divanillyltetrahydrofuran

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1659179

Country of ref document: EP